BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
FABP1
,
Metabolism of xenobiotics
,
Breast Cancer
,
Prostate
,
Neocentromeres
,
rs7903146
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
EVI1_03
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Jejunum
Frontal lobe
Skeletal muscle
Prefrontal cortex
Parietal lobe
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Pyloric ulcer
Vesicular stomatitis Indiana virus disease
Barrett's esophagus
Esophagitis
Duchenne muscular dystrophy
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
A 443654
CGP 60474
Glesatinib
NVP-BHG712
flavopiridol
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
MIR122
PPP2R2C
NOP2
NR5A1
PCDH11X
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Hemin treatment, GATA1, EKLF or NF-E2 over-expressing and knocking-down in K562 cells
miRNA expression in childhood adrenocortical tumors
L1000 CMAP - Bone marrow CD34 cells treated with small molecule perturbagens
MicroRNA expression profiling of human adrenal pheochromocytomas
HBV-positive liver carcinoma cell line miRNA expression
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for EVI1_03
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Novel Approaches to Target MECOM/EVI1 in AML
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ